The Department of Health had up to one year to act on the recommendations of the Board. In a move that excited patients and advocates, Dr. Rachel Levine on behalf of the Department acted quickly adopting all of the recommendations above.
What will this mean for Pennsylvania’s medical marijuana patients? The added indications will create a more inclusive program. The inclusion of flower to the program will provide added relief to many patients, including those with PTSD. Optimistically, this NORML Executive Director sees this as an even greater victory as it puts into place all of the instruments necessary to handle the eventual statewide LEGAL sale of recreational marijuana.
The enactment of marijuana legalization laws is associated with a significant reduction in the number of opioids prescribed and filled, according to a pair of studies published online today in the journal JAMA Internal Medicine.
In his ongoing effort to expand the Garden State’s medical marijuana program to be more patient-oriented, Governor Phil Murphy (D-NJ) has made dramatic changes to the state’s regulatory program.
Senate lawmakers this week passed legislation, Senate Bill 1120, that seeks to preemptively quash many of the provisions of State Question 788 — an expansive voter initiative that provides physicians the discretion to recommend medical marijuana to those patients for whom they believe it will therapeutically benefit.
Proponents of a Missouri voter initiative effort to legalize and regulate the therapeutic use and distribution of cannabis statewide have surpassed over 200,000 signatures. Advocates must collect a total of 160,000 qualified signatures in six of Missouri’s eight congressional districts by May 6, 2018 in order to qualify the measure for the 2018 electoral ballot.
Members of Virginia NORML played an instrumental role in the recent passage of legislation that will expand Virginia’s limited medical marijuana program from a single qualifying disorder program to include any diagnosed condition.
Democrat Gov. Phil Murphy signed an executive order on Tuesday calling on state regulators to review the state’s eight-year-old medical cannabis access program and to recommend ways to increase participation from patients and physicians. “Our goal is to modernize the program in New Jersey, bring it up to current standards, and put patients first,” he said.
A recently approved plan by the members of the US House and Senate to temporarily extend federal funding through February 8, 2018 also extends provisions protecting statewide medical cannabis programs from federal interference.